Feb 10, 2023; Oslo, Norway: Today, on the eve of International Day of Women and Girls in Science, the Coalition for Epidemic Preparedness Innovations (CEPI) launched their #AskWomenInScience campaign, which will spotlight the crucial role of women in science while advocating for greater gender equality in science. Aspiring girl and women scientists are invited to submit their questions about what it is like being a woman at the cutting edge of vaccine science.
CEPI is welcoming questions across a broad range of topics: from what their proudest achievement is, their route into science, to the barriers they’ve had to overcome during their careers.
A selection of the questions will be answered by a group of CEPI’s women scientists and shared across CEPI’s digital platforms on International Women’s Day, 8 March.
The gender imbalance in science is striking – according to the UN, just 30% of science researchers identify as women. Through the #AskWomenInScience campaign, CEPI hopes to open a dialogue around this issue whilst also answering some of the most burning questions that aspiring girl or women scientists will have.
Executive Director of Vaccine Research and Development, CEPI
Note to editors
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched in 2017, to develop vaccines against future epidemics. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need.
Prior to COVID-19, CEPI’s work focused on developing vaccines against Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus – it has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X).
CEPI has played a central role in the global response to COVID-19, supporting the development of the world’s largest portfolio of vaccines against SARS-CoV-2 and its variants with a focus on speed, scale and access, as well as co-leading COVAX, the global initiative to deliver fair and equitable access to COVID-19 vaccines. CEPI is also the world’s leading funder of R&D for broadly protective coronavirus vaccines which could protect against future variants of COVID-19 as well as other coronaviruses with epidemic and pandemic potential.
CEPI has embarked upon an ambitious US$3.5bn five-year plan – called CEPI 2.0 – to dramatically reduce or even eliminate the future risk of pandemics and epidemics. Central to the plan is CEPI’s goal – supported by the G7 and G20 – to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days. Achieving this ‘100 Days Mission’ would give the world a fighting chance of containing a future outbreak before it spreads to become a global pandemic. Read the plan at endpandemics.cepi.net/
Email: [email protected]
Tel: +44 7387 055214